Abstract
In this chapter we would like to review the historical development and use of two anti-folate thymidylate synthase (TS) inhibitors which have so far reached clinical study, CB 3717 and ICI D1694 (Figure 1). Both agents first entered clinical trial at the Royal Marsden Hospital, the clinical centre attached to the Institute of Cancer Research (ICR), CB 3717 in September 1981 and ICI D1694, a decade later in February 1991.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
A.L. Jackman, G.A. Taylor, A.H. Calvert and K.R. Harrap, Modulation of Anti-metabolite Effects: Effects of thymidine on the efficacy of the quinazoline-based thymidylate synthetase inhibitor, CB3717. Biochem Pharmacol, 33 (1984) 3269–3275.
A. Lockshin and P.V. Danenberg, Biochemical factors affecting the tightness of 5-fluorodeoxyuridylate binding to human thymidylate synthetase. Biochem Pharmacol, 30 (1981) 247–257.
O.D. Bird, J.W. Vaitkus and J. Clarke, 2-Amino-4-hydroxyquinazolines as inhibitors of thymidylate synthetase. Molec Pharmacol, 6 (1970) 573–575.
A.L. Jackman, T.R. Jones and A.H. Calvert, Thymidylate synthetase inhibitors: experimental and clinical aspects. In F.M. Muggia (ed.), Experimental and clinical progress in cancer chemotherapy, Martinus Nijhoff, Boston, 1985, pp. 155–209.
T.R. Jones, A.H. Calvert, A.L. Jackman, S.J. Brown, M. Jones and K.R. Harrap, A potent antitumour quinazoline inhibitor of thymidylate synthetase: synthesis, biological properties and therapeutic results in mice. Europ J Cancer, 17 (1981) 11–19.
H. Diddens, D. Niethammer and R.C. Jackson, Patterns of cross-resistance to the antifolate drugs trimetrexate, metoprine, homofolate, and CB3717 in human lymphoma and osteosarcoma cells resistant to methotrexate. Cancer Res, 43 (1983) 5286–5292.
Y-C. Cheng, G.E. Dutschman, M.C. Starnes, M.H. Fisher, N.T. Nanavathi and M.G. Nair, Activity of the new antifolate N10-propargyl-5,8-dideazafolate and its polyglutamates against human dihydrofolate reductase, human thymidylate synthetase, and KB cells containing different levels of dihydrofolate reductase. Cancer Res, 45 (1985) 598–600.
E. Sikora, A.L. Jackman, D.R. Newell and A.H. Calvert, Formation and retention and biological activity of N10-propargyl-5,8-dideazafolic acid (CB3717) polyglutamates in L1210 cells in vitro. Biochem Pharmacol, 37 (1988) 4047–4054.
A.H. Calvert, D.L. Alison, SJ. Harland, B.A. Robinson, A.L. Jackman, T.R. Jones, D.R. Newell, Z.H. Siddik, E. Wiltshaw, T.J. McElwain, I.E. Smith and K.R. Harrap, A phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N10-propargyl-5,8-dideazafolic acid, CB3717. J Clin Oncol, 4 (1986) 1245–1252.
S. Vest, E. Bork and H.H. Hansen, A phase I evaluation of N10-propargyl-5,8-dideazafolic acid. Eur J Cancer Clin Oncol, 24 (1988) 201–204.
C. Sessa, M. Zucchetti, M. Ginier, Y. Willems, M. D’lncalci and F. Cavalli, Phase I study of the antifolate N10-propargyl-5,8-dideazafolic acid, CB3717. Eur J Cancer Clin Oncol, 24 (1988) 769–775.
B.M.J. Cantwell, M. Earnshaw and A.L. Harris, Phase II study of a novel antifolate, N10-propargyl-5,8-dideazafolic acid (CB3717), in malignant mesothelioma. Cancer Treat Rep, 70 (1986) 1335–1336.
B.M.J. Cantwell, V. Macaulay, A.L. Harris, S.B. Kaye, I.E. Smith, R.A.V. Milsted and A.H. Calvert, Phase II study of the antifolate N10-propargyl-5,8-dideazafolic acid (CB3717) in advanced breast cancer. Eur J Cancer Clin Oncol, 24 (1988) 733–736.
M.J. Harding, B.M.J. Cantwell, R.A.V. Milstead, A.L. Harris and S.B. Kaye, Phase II study of the thymidylate synthetase inhibitor CB3717 (N10-propargyl-5,8-dideazafolic acid) in colorectal cancer. Br J Cancer, 57 (1988) 628–629.
M.F. Bassendine, N.J. Curtin, H. Loose, A.L. Harris and Q.F.W. James, Induction of remission in hepatocellular carcinoma with a new thymidylate synthase inhibitor, CB3717. J Hepatol, 4 (1987) 349–356.
D.R. Newell, D.L. Alison, A.H. Calvert, K.R. Harrap, M. Jarman, T.R. Jones, M. Manteuffel-Cymborowska and P. O’Connor, Pharmacokinetics of the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB3717) in the mouse. Cancer Treat Rep, 70 (1986) 971–979.
D.L. Alison, D.R. Newell, C. Sessa, S.J. Harland, LI. Hart, K.R. Harrap and A.H. Calvert, The clinical pharmacokinetics of the novel antifolate N10-propargyl-5,8-dideazafolic acid (CB3717). Cancer Chemother Pharmacol, 14 (1985) 265–271.
D.I. Jodrell, D.R. Newell, S.E. Morgan, S. Clinton, J.P.M. Bensted, LR. Hughes and A.H. Calvert, The renal effects of N10-propargyl-5,8-dideazafolic acid (CB3717) and a non-nephrotoxic analogue ICI D1694, in mice. Br J Cancer, 64 (1991) 833–838.
T.R. Jones, T.J. Thornton, A. Flinn, A.L. Jackman, D.R. Newell and A.H. Calvert, Quinazoline antifolates inhibiting thymidylate synthase: 2-desamino derivatives with enhanced solubility and potency. J Med Chem, 32 (1989) 847–852.
K.R. Harrap, A.L. Jackman, D.R. Newell, G.A. Taylor, LR. Hughes and A.H. Calvert, Thymidylate synthase: a target for anticancer drug design. In G. Weber (ed.), Advances in Enzyme Regulation, Pergamon, Oxford, 1989, pp. 161–179.
A.L. Jackman, G.A. Taylor, B.M. O’Connor, J.A. Bishop, R.G. Moran and A.H. Calvert, Activity of the thymidylate synthase inhibitor 2-desamino-N10-propargyl-5,8-dideazafolic acid and related compounds in murine (L1210) and human (W1L2) systems in vitro and in L1210 in vivo. Cancer Res, 50 (1990) 5212–5218.
L.R. Hughes, A.L. Jackman, J. Oldfield, R.C. Smith, K.D. Burrows, P.R. Marsham, J.A. Bishop, T.R. Jones, B.M. O’Connor and A.H. Calvert, Quinazoline antifolate thymidylate synthase inhibitors: alkyl, substituted alkyl, and aryl substituents in the C2 position. J Med Chem, 33 (1990) 3060–3067.
A.L. Jackman, D.R. Newell, W. Gibson, D.I. Jodrell, G.A. Taylor, J.A. Bishop, LR. Hughes and A.H. Calvert, The biochemical pharmacology of the thymidylate synthase inhibitor, 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583). Biochem Pharmacol, 42 (1991) 1885–1895.
P.R. Marsham, L.R. Hughes, A.L Jackman, A.J. Hayter, J. Oldfield, J.M. Wardleworth, J.A. Bishop, B.M. O’Connor and A.H. Calvert, Quinazoline antifolate thymidylate synthase inhibitors: heterocyclic benzoyl ring modifications. J Med Chem, 34 (1991) 1594–1605.
A.L Jackman, G.A. Taylor, W. Gibson, R. Kimbell, M. Brown, A.H. Calvert, I.R. Judson and L.R. Hughes, ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res, 51 (1991) 5579–5586.
T.C. Stephens, B.E. Valcaccia, M.L Sheader, L.R. Hughes and A.L. Jackman, The thymidylate synthase (TS) inhibitor ICI D1694 is superior to CB3717, 5-fluorouracil(5-FU) and methotrexate (MTX) against a panel of human tumor xenografts. Proc Amer Assoc Cancer Res, 32 (1991) 328.
A.L. Jackman, D.I. Jodrell, W. Gibson and T.C. Stephens, ICI D1694, an inhibitor of thymidylate synthase for clinical study. In R.A. Harkness, G. Elion and N. Zollner (eds.), Purine and pyrimidine metabolism in man VII, Plenum Press, New York, 1991, pp. 19–23.
N.J. Curtin, A.L. Harris, O.F.W. James and M.F. Bassendine, Inhibition of the growth of human hepatocellular carcinoma in vitro and in athymic mice by a quinazoline inhibitor of thymidylate synthase, CB3717. Br J Cancer, 53 (1986) 361–368.
D.I. Jodrell, D.R. Newell, W. Gibson, L.R. Hughes and A.H. Calvert, The pharmacokinetics of the quinazoline antifolate ICI D1694 in mice and rats. Cancer Chemother Pharmacol, 28 (1991) 331–338.
T.C. Stephens, J.A. Calvete, D. Janes, L.R. Hughes, A.L. Jackman and A.H. Calvert, Assessment of quinazoline thymidylate synthase (TS) inhibitors using a thymidine kinase deficient cell line (L5178Y TK-/-). Proc Amer Assoc Cancer Res, 30 (1989) 477.
T.C. Stephens, J.A. Calvete, D. Janes, S.E. Waterman, B.E. Valcaccia, L.R. Hughes and A.H. Calvert, Antitumour activity of a new thymidylate synthase (TS) inhibitor, D1694. Proc Amer Assoc Cancer Res, 31 (1990) 342.
D.R. Newell, D.L. Alison, A.L. Jackman, C. Sessa, A.H. Calvert and K.R. Harrap, Clinical and preclinical pharmacokinetic studies with the thymidylate synthetase (TS) inhibitor N10-propargyl-5,8-dideazafolic acid (CB3717). Proc Amer Assoc Cancer Res, 26 (1985) 350.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer Science+Business Media New York
About this chapter
Cite this chapter
Clarke, S.J., Jackman, A.L., Judson, I.R. (1993). The History of the Development and Clinical Use of CB 3717 and ICI D1694. In: Rustum, Y.M. (eds) Novel Approaches to Selective Treatments of Human Solid Tumors. Advances in Experimental Medicine and Biology, vol 339. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2488-5_27
Download citation
DOI: https://doi.org/10.1007/978-1-4615-2488-5_27
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6060-5
Online ISBN: 978-1-4615-2488-5
eBook Packages: Springer Book Archive